Inevitable price reduction of simvastatin preparations probable

Published: 2003-03-25 06:57:00

Updated: 2003-03-25 06:57:00

Influenced by the voluntary reimbursement price cut of MSD Korea's Zocor, which has dominated the domestic anti-hyperlipemic market, the overall price of its generic versions seems likely to be lowered in rows.

MSD Korea said that from this April its insurance price of Zocor 40mg will be reduc...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK